Beijing Tiantan Hospital
首都医科大学附属北京天坛医院
Listed for 15 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
Official links opened and checked on 2026-11-08.
Research at Beijing Tiantan Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Chordoma脊索瘤14 papers led
- Osteosarcoma骨肉瘤0 papers led
- Neuroblastoma神经母细胞瘤0 papers led
- Haemophilia A血友病 A1 paper led
- Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病34 papers led2 open trials led
- Myasthenia gravis重症肌无力1 paper led
- Moyamoya disease烟雾病60 papers led9 open trials led
- Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎6 papers led
- Takayasu arteritis大动脉炎1 paper led
- Idiopathic pulmonary fibrosis特发性肺纤维化2 papers led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症4 papers led
- Spinal muscular atrophy脊髓性肌萎缩症0 papers led
- Duchenne muscular dystrophy杜氏肌营养不良1 paper led
- Niemann–Pick disease type C尼曼-匹克病 C 型0 papers led
- Leber hereditary optic neuropathyLeber 遗传性视神经病变1 paper led
Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Hepatoblastoma, Retinoblastoma, Gastrointestinal stromal tumour, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, IgG4-related disease, Wilson disease, Biliary atresia, Hepatic echinococcosis, Lymphangioleiomyomatosis, Fabry disease, Pompe disease, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Chordoma
脊索瘤Led 14 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 13.3%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Beijing for chordoma88 hospitals in China for chordoma
No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led14
- Enhancing Chordoma Radiotherapy: Ta@PVP Nanoparticles as Potent Radiosensitizers.
- Development and validation of basement membrane-related signatures for predicting postoperative recurrence, tumor microenvironment and drug candidates in chordomas.
- Radiogenomic method combining DNA methylation profiles and magnetic resonance imaging radiomics predicts patient prognosis in skull base chordoma.
- Endoplasmic reticulum stress-related cancer-associated fibroblast confers adverse prognosis and therapeutic vulnerability in skull base chordoma.
- The novel developed and validated multiparametric MRI-based fusion radiomic and clinicoradiomic models predict the postoperative progression of primary skull base chordoma.
- Function and regulation of miR-186-5p, miR-125b-5p and miR-1260a in chordoma.
- Unravelling the role of immune cells and FN1 in the recurrence and therapeutic process of skull base chordoma.
- Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes.
- Mid-term follow-up surgical results in 284 cases of clival chordomas: the risk factors for outcome and tumor recurrence.
- Survival and treatment of cranial and spinal chordomas: a population-based study.
- TGFB3 downregulation causing chordomagenesis and its tumor suppression role maintained by Smad7.
- DEPDC1B regulates the progression of human chordoma through UBE2T-mediated ubiquitination of BIRC5.
- Loss of SMARCB1 promotes autophagy and facilitates tumour progression in chordoma by transcriptionally activating ATG5.
- Whole genome sequencing of skull-base chordoma reveals genomic alterations associated with recurrence and chordoma-specific survival.
Earlier papers (2016–2020)30
- MRI Signal Intensity and Electron Ultrastructure Classification Predict the Long-Term Outcome of Skull Base Chordomas.
- LncRNA and mRNA expression profiles reveal the potential roles of lncRNA contributing to regulating dural penetration in clival chordoma.
- Mean platelet volume and platelet distribution width serve as prognostic biomarkers in skull base chordoma: a retrospective study.
- High expression of survivin independently correlates with tumor progression and mortality in patients with skull base chordomas.
- A Series of 62 Skull Base Chordomas in Pediatric and Adolescent Patients: Clinical Characteristics, Treatments, and Outcomes.
- Natural Growth Dynamics of Untreated Skull Base Chordomas In Vivo.
- Benign notochordal cell tumour: clinicopathology and molecular profiling of 13 cases.
- Combination of PARP inhibitor and temozolomide to suppress chordoma progression.
- High Expression of TGF-β1 Predicting Tumor Progression in Skull Base Chordomas.
- Differential Diagnosis and Treatment Modality of Parasellar Plasmacytoma: Clinical Series and Literature Review.
- SNF5 as a prognostic factor in skull base chordoma.
- Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma.
- Aberrant Expression of Extracellular Signal-Regulated Kinase and 15-Hydroxyprostaglandin Dehydrogenase Indicates Radiation Resistance and Poor Prognosis for Patients with Clival Chordomas.
- MR Imaging Grading System for Skull Base Chordoma.
- Effect comparisons among treatment measures on progression-free survival in patients with skull base chordomas: a retrospective study of 234 post-surgical cases.
- Clinical features and surgical outcomes of patients with skull base chordoma: a retrospective analysis of 238 patients.
- In Reply to the Letter to the Editor Regarding "Expression of Cathepsin K in Skull Base Chordoma".
- In Reply to the Letter to the Editor Regarding "Expression of Cathepsin K in Skull Base Chordoma".
- In Reply to "Ki-67 Index as a Prognostic Marker in Chordomas: A Systematic Review of the Literature".
- In Reply to "Prognostic Significance of Resection Degree in Skull Base Chordoma: A Systematic Review and Meta-Analysis".
- Expression of Cathepsin K in Skull Base Chordoma.
- Prognostic Value of a Category Based on Electron Microscopic Features of Clival Chordomas.
- Clinical Features and Prognostic Factors of Children and Adolescents with Clival Chordomas.
- Factors for Overall Survival in Patients with Skull Base Chordoma: A Retrospective Analysis of 225 Patients.
- Differences in Dural Penetration of Clival Chordomas Are Associated with Different Prognosis and Expression of Platelet-Derived Growth Factor Receptor-β.
- Factors for tumor progression in patients with skull base chordoma.
- Bone invasiveness is associated with prognosis in clivus chordomas.
- Classification and surgical approaches for transnasal endoscopic skull base chordoma resection: a 6-year experience with 161 cases.
- Analysis of Clinical Features and Outcomes of Skull Base Chordoma in Different Age-Groups.
- Proposal and Validation of a Basic Progression Scoring System for Patients with Skull Base Chordoma.
All its trials on ClinicalTrials.gov, any status1
Cancer
Osteosarcoma
骨肉瘤Led no English-language PubMed papers on osteosarcoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
48 hospitals in Beijing for osteosarcoma742 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Neuroblastoma
神经母细胞瘤Led no English-language PubMed papers on neuroblastoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
24 hospitals in Beijing for neuroblastoma352 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Blood disorders
Haemophilia A
血友病 ALed 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
15 hospitals in Beijing for haemophilia A160 hospitals in China for haemophilia A
No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Neuromyelitis optica spectrum disorder
视神经脊髓炎谱系疾病Led 34 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 7.0%.
12 hospitals in Beijing for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder
Open trials with this hospital 5
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingClinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
- Phase
- Not given
- Started
- 2019-01
- Registry
- NCT04106830
Age 16 years to 75 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- Enrolling by invitationNormal Chinese Lifespan Brain Charts Initiative (NCLBCI)
- Phase
- Not given
- Started
- 2023-12
- Registry
- NCT06643858
Age 6 years to 90 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- RecruitingA Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
- Phase
- Phase 2/Phase 3
- Started
- 2024-07
- Registry
- NCT06413654
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou
- RecruitingClinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
- Phase
- Early phase 1
- Started
- 2022-04
- Registry
- NCT05145361
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Taiyuan, Tianjin, Xi'an
- Not yet recruitingCrisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
- Phase
- Phase 4
- Started
- 2026-06
- Registry
- NCT07699770
Age 18 years to 75 years (registered criteria)
Led by Tangdu Hospital; 5 listed hospitals as study sitesBeijing, Changchun, Chongqing, Kunming, Shenyang, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led34
- Serum GPR37 as a novel biomarker for disease activity, disability, and differential diagnosis in NMOSD.
- Deep Gray Matter Iron Deposition in NMOSD and MOGAD: A Comparative Study with MS.
- Oligodendroglia in Neuromyelitis Optica Spectrum Disorder.
- Spatiotemporal subtypes of brain and spinal cord atrophy in neuromyelitis optica spectrum disorders and multiple sclerosis.
- Diagnostic biomarkers for differentiating AQP4-IgG- negative NMOSD from other nervous system autoimmune disorders: a retrospective study.
- Estimated Brain Age in Healthy Aging and Across Multiple Neurological Disorders.
- Cerebrospinal fluid interleukin-6 may be a biomarker for conversion of clinically isolated syndrome to neuromyelitis optica spectrum disorder.
- Imaging Transcriptomics of Brain Functional Alterations in MS and Neuromyelitis Optica Spectrum Disorder.
- Identification of potential biomarkers for neuromyelitis optica by quantitative proteomics.
- Distinct virtual histology of grey matter atrophy in four neuroinflammatory diseases.
- Efficacy and safety of apheresis therapy in AQP4 antibody-positive NMOSD attack: A propensity score-matched cohort study.
- The landscape of PBMCs in AQP4-IgG seropositive NMOSD and MOGAD, assessed by high dimensional mass cytometry.
- Efficacy and safety of low- and ultralow-dose rituximab in neuromyelitis optica spectrum disorder.
- Spinal cord and brain atrophy patterns in neuromyelitis optica spectrum disorder and multiple sclerosis.
- Independent and reproducible hippocampal radiomics biomarkers for multisite multiple sclerosis and neuromyelitis optica spectrum disorders.
- APOE from patient-derived astrocytic extracellular vesicles alleviates neuromyelitis optica spectrum disorder in a mouse model.
- Targeting chemoattractant chemokine (C-C motif) ligand 2 derived from astrocytes is a promising therapeutic approach in the treatment of neuromyelitis optica spectrum disorders.
- Brain age gap in neuromyelitis optica spectrum disorders and multiple sclerosis.
- Tocilizumab treatment in neuromyelitis optica spectrum disorders: Updated meta-analysis of efficacy and safety.
- Establishment of a comprehensive diagnostic model for neuromyelitis optica spectrum disorders based on the analysis of laboratory indicators and clinical data.
- The difference of the retinal structural and microvascular characteristics in patients with MOGAD-ON and AQP4-ON.
- A prospective study on tryptophan immunoadsorption in AQP4 antibody-positive neuromyelitis optica spectrum disorders.
- Structural and functional hippocampal alterations in Multiple sclerosis and neuromyelitis optica spectrum disorder.
- NMO-IgG Induce Interleukin-6 Release via Activation of the NF-κB Signaling Pathway in Astrocytes.
- Thymic Involution and Altered Naive CD4 T Cell Homeostasis in Neuromyelitis Optica Spectrum Disorder.
- Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS.
- Brain structural and functional alterations in MOG antibody disease.
- Efficacy of mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
- The occurrence of myelin oligodendrocyte glycoprotein antibodies in aquaporin-4-antibody seronegative Neuromyelitis Optica Spectrum Disorder: A systematic review and meta-analysis.
- Elevated chemokines and cytokines for eosinophils in neuromyelitis optica spectrum disorders.
- Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
- Timing of plasma exchange for neuromyelitis optica spectrum disorders: A meta-analysis.
- B-Cell Compartmental Features and Molecular Basis for Therapy in Autoimmune Disease.
- Persistently Gadolinium-Enhancing Lesion Is a Predictor of Poor Prognosis in NMOSD Attack: a Clinical Trial.
Chinese-language papers (not in the count)2
All its trials on ClinicalTrials.gov, any status8
- Normal Chinese Lifespan Brain Charts Initiative (NCLBCI)
- Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
- Sensitivity and Specificity of TSA-CBA for Autoantibodies Against Neural Antigen Determination
- China National Registry of Neuro-Inflammatory Diseases
- Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
- A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
- Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
- A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
More papers found outside PubMed (not counted)5
- Choroid Plexus Cysts on 7T MRI Differentiate NMOSD from MS
- Development and Validation of a Differential Diagnostic Models for Guillain–Barré Syndrome Based on Clinical and Laboratory Indicators: A Retrospective Study
- Progress on single-cell sequencing technology in central nervous system autoimmune diseases
- A Multisite and Multimodal Comparative Study of Cerebellar Connectome Between Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders
- Magnetic resonance imaging markers for multiple sclerosis and neuromyelitis optica spectrum disorders
Other diseases
Myasthenia gravis
重症肌无力Led 1 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
11 hospitals in Beijing for myasthenia gravis93 hospitals in China for myasthenia gravis
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingEfficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
- Phase
- Phase 2
- Started
- 2022-07
- Registry
- NCT05067348
Age 18 years to 80 years (registered criteria)
Led by Tangdu Hospital; 5 listed hospitals as study sitesBeijing, Changsha, Chengdu, Shanghai, Tianjin, Xi'an
- RecruitingA Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Phase
- Phase 3
- Started
- 2021-07
- Registry
- NCT04951622
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led1
All its trials on ClinicalTrials.gov, any status7
- Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
- A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases
- Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis
- A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
- The Specificity, Sensitivity and Clinical Correlation of CBA, RIPA and ELISA in Detecting AChR and MuSK IgG of Myasthenia Gravis
- A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis
Other diseases
Moyamoya disease
烟雾病Led 60 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 16.9%.
- Open trials as a site
- 0
- led by another institution
8 hospitals in Beijing for moyamoya disease47 hospitals in China for moyamoya disease
Open trials with this hospital 9
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingEfficacy and Safety of Ischemic Preconditioning Therapy Versus Optimal Medical Therapy in Reducing the Recurrence of Ischemic Events in Symptomatic Moyamoya Disease
- Phase
- N/A
- Started
- 2026-10
- Registry
- NCT07889531
Age 18 years to 70 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- RecruitingDevelopment and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07894107
Age 12 years to 70 years (registered criteria)
Led by Beijing Tiantan Hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanchang, Shanghai, Suzhou, Wuhan, Zhengzhou
- RecruitingStudy on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya Disease
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT06817434
Age 18 years to 60 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- RecruitingStudy on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT06832839
Age 18 years to 60 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- RecruitingFamily-Based Moyamoya Susceptibility and Early Detection
- Phase
- Not given
- Started
- 2024-11
- Registry
- NCT07517354
Age not stated (registered criteria)
Led by Beijing Tiantan Hospital; 1 listed hospital as study siteBeijing
- RecruitingFunctional Magnetic Resonance-Based Observations of Brain Networks in Moyamoya Disease Patients Under Anesthesia
- Phase
- Not given
- Started
- 2023-10
- Registry
- NCT06041659
Age 18 years to 65 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- RecruitingLong-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA)
- Phase
- Not given
- Started
- 2022-05
- Registry
- NCT05332756
Age 2 years to 60 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- RecruitingRegistry of Multicenter Brain-Heart Comorbidity in China
- Phase
- Not given
- Started
- 2012-01
- Registry
- NCT05961748
Age 18 years to Not stated (registered criteria)
Led by Beijing Tiantan Hospital; 4 listed hospitals as study sitesBeijing, Harbin, Shanghai, Zhengzhou
- Not yet recruitingEvaluating Antiplatelet and Physical Therapy for Slowing Progression in Mild Moyamoya Disease.
- Phase
- N/A
- Started
- 2026-07
- Registry
- NCT07762547
Age 18 years to 70 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led60
- Integrated bulk RNA sequencing and mass cytometry analysis reveal the circulating immune landscape in ischemic and hemorrhagic Moyamoya disease.
- Serum Creatine Levels as a Predictive Factor for Postoperative Cerebrovascular Events in Patients With Moyamoya Disease.
- Unraveling the Dyslipidemic Landscape in Moyamoya Disease: OxLDL as a Key Biomarker.
- Taurine levels and long-term adverse cerebrovascular risk in moyamoya disease: A prognostic perspective study.
- Innate Immune Cell Profiling in Peripheral Blood Mononuclear Cells of Patients with Moyamoya Disease.
- Circulating T cell atlas in Moyamoya disease: insights into immunopathogenesis of cerebrovascular disorders.
- Serum amyloid A2-induced phenotypic switching of vascular smooth muscle cells in moyamoya disease.
- Improvement in multiple cognitive domains via combined revascularization by 6 months' follow-up: a new potential surgical indication in moyamoya disease.
- RNF213 Variant and Infectious Burden Associated With Intracranial Artery Stenosis in Moyamoya Disease.
- Comprehensive Analysis and In Vitro Verification of Endothelial-Mesenchymal Transition-Related Genes in Moyamoya Disease.
- Choroid plexus enlargement correlates with cognitive dysfunction and disease progression in Moyamoya disease.
- Angiogenesis-related genes and immune microenvironment in moyamoya disease: a transcriptomic and functional analysis.
- Deep-learning tool for early identification of non-traumatic intracranial hemorrhage etiology and application in clinical diagnostics based on computed tomography (CT) scans.
- Reorganization of gray matter networks in patients with Moyamoya disease.
- Understanding external carotid artery collateralisation after cerebral revascularisation in moyamoya disease: insights from quantitative analysis.
- Association Between Folate Metabolism Risk, Collateral Circulation, and Hemorrhagic Risk in Moyamoya Disease.
- Alterations in the Glymphatic System and Association with Brain Structure and Cognitive Function in Moyamoya Disease.
- Glymphatic Impairment Associated with Neurocognitive Dysfunction in Moyamoya Disease.
- Age-Dependent Risk Factors for Hemorrhagic Events in Moyamoya Disease: The Role of Collateral Vessels.
- Differential WNT4 expression among various subtypes of moyamoya disease results in alterations of microtubule stability.
- Circulating immune cell landscape and T-cell abnormalities in patients with moyamoya disease.
- Association of lysine pathway metabolites with moyamoya disease.
- Mass cytometry revealed the circulating immune cell landscape across different Suzuki stages of Moyamoya disease.
- A novel system for evaluating collateralization of the external carotid artery after cerebral revascularization in moyamoya disease.
- Effectiveness of indirect revascularization for adult hemorrhagic moyamoya disease: a 10-year follow-up study.
- Nonalcoholic fatty liver disease is an independent risk factor for ischemic stroke after revascularization in patients with Moyamoya disease: a prospective cohort study.
- Prognostic value of morphology and hemodynamics in moyamoya disease for long-term outcomes and disease progression.
- Characterization of PANoptosis-related genes and the immune landscape in moyamoya disease.
- A Vessel Wall MRI Investigation in Patients With Moyamoya or Quasi-Moyamoya Disease: Diagnosis, Features, and Outcomes.
- Nomogram to Predict Good Neoangiogenesis After Indirect Revascularization Surgery in Patients with Moyamoya Disease: a Case-control Study.
- Risk Factors for Specific Postoperative Ischemic Complications in Patients with Moyamoya Disease: A Single-Center Retrospective Study.
- Long-Term Clinical Outcomes After Cerebral Revascularization in Moyamoya Disease With Extracranial Internal Carotid Artery Occlusion.
- The prognostic nutrition index is a predictor for long-term outcomes after revascularization in adult moyamoya disease.
- Association between systemic immune-inflammatory markers and the risk of moyamoya disease: a case-control study.
- Integrated analysis of the association between methionine cycle and risk of moyamoya disease.
- Metabolomic signatures associated with pathological angiogenesis in moyamoya disease.
- Application of Induced Pluripotent Stem Cells in Moyamoya Disease: Progress and Promises.
- Gut microbiota in adults with moyamoya disease: characteristics and biomarker identification.
- RNA profiling of sEV (small extracellular vesicles)/exosomes reveals biomarkers and vascular endothelial dysplasia with moyamoya disease.
- Fetal posterior cerebral artery in pediatric and adult moyamoya disease: A single-center experience of 480 patients.
- Association between DIAPH1 variant and posterior circulation involvement with Moyamoya disease.
- Upregulated Cytoskeletal Proteins Promote Pathological Angiogenesis in Moyamoya Disease.
- Hemorrhage Risk in Moyamoya Disease with Fetal-Type Posterior Cerebral Artery: A Propensity Score-Matched Analysis.
- Predictors of preoperative cognitive dysfunction in adults with Moyamoya disease: a preliminary research.
- Recurrent Artery of Heubner Aneurysm Masquerading as Caudate Hemorrhage without Subarachnoid Hemorrhage in Moyamoya Disease: A Case Report and Literature Review.
- Infarction Patterns and Recurrent Adverse Cerebrovascular Events in Moyamoya Disease.
- Epigenome-Wide Association Study Reveals Differential Methylation Sites and Association of Gene Expression Regulation with Ischemic Moyamoya Disease in Adults.
- Association of RNF213 Variants With Periventricular Anastomosis in Moyamoya Disease.
- Assessment of Surgical Outcomes in Children and Adult Ischemic Moyamoya Disease and Its Relationship with the Pre-infarction Cerebral Perfusion Status.
- Intraoperative transit-time ultrasonography combined with FLOW800 predicts the occurrence of cerebral hyperperfusion syndrome after direct revascularization of Moyamoya disease: a preliminary study.
- Risk factors for postoperative ischemic complications in pediatric moyamoya disease.
- Changes of cerebral cortical structure and cognitive dysfunction in "healthy hemisphere" after stroke: a study about cortical complexity and sulcus patterns in bilateral ischemic adult moyamoya disease.
- Impairments in brain perfusion, executive control network, topological characteristics, and neurocognition in adult patients with asymptomatic Moyamoya disease.
- Clinical Implications of the "Brush Sign" in Susceptibility-Weighted Imaging for Moyamoya Disease.
- Assessment of blood supply of the external carotid artery in moyamoya disease using super-selective pseudo-continuous arterial spin labeling technique.
- Letter to the Editor Regarding "Clinical Prediction of Surgical Revascularization Outcome in Moyamoya Disease Via Transcranial Color Sonography".
- Hyperhomocysteinemia is a risk factor for postoperative ischemia in adult patients with moyamoya disease.
- Intraoperative local hemodynamic quantitative analysis of direct revascularization in patients with moyamoya disease.
- Effects and safety of aspirin use in patients after cerebrovascular bypass procedures.
- Haemodynamic analysis of adult patients with moyamoya disease: CT perfusion and DSA gradings.
All its trials on ClinicalTrials.gov, any status17
- Evaluating Antiplatelet and Physical Therapy for Slowing Progression in Mild Moyamoya Disease.
- Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
- Efficacy and Safety of Ischemic Preconditioning Therapy Versus Optimal Medical Therapy in Reducing the Recurrence of Ischemic Events in Symptomatic Moyamoya Disease
- Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease
- Study on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya Disease
- Family-Based Moyamoya Susceptibility and Early Detection
- Functional Magnetic Resonance-Based Observations of Brain Networks in Moyamoya Disease Patients Under Anesthesia
- Long-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA)
- Registry of Multicenter Brain-Heart Comorbidity in China
- Prognostic Prediction Model in Patients With Moyamoya Disease Undergoing Revascularization Surgery
- Gut Microbiota in Patients With Moyamoya Disease
- The Role of m6A RNA Modification in Moyamoya Disease
- RNF213 Variants and Collateral Vessels in Moyamoya Disease
- Effects of Remote Ischemic Pre-Conditioning in Moyamoya Disease Patients
- Direct Bypass Versus Indirect Bypass in Treatment of Adults Hemorrhagic Moyamoya Disease
- NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events
- Precision Bypass in Patients With Moyamoya Disease
More papers found outside PubMed (not counted)7
- Divergent Phenotypes and Persistent Disability: A Comparative Cohort Study of Arterial Ischaemic and Haemorrhagic Stroke in Chinese Paediatric Patients
- 甘油三酯-葡萄糖指数在烟雾病患者中的特征分析:1项病例对照研究(Analysis of Triglyceride-Glucose Index Characteristics in Patients with Moyamoya Disease: A Case-Control Study)
- RNA methylation-driven molecular subtypes and immune infiltration in Moyamoya disease
- Deep Learning Approach to Predict Hemorrhage in Moyamoya Disease
- Deep-Learning Tool for Early Identifying Non-Traumatic Intracranial Hemorrhage Etiology based on CT Scan
- Short⁃term neurological function and clinical symptom improvement after cerebral revascularization in adults with moyamoya disease: a single⁃center study
- A Practical Questionnaire and Literature Review: Dose Suzuki Grading Still the Gold Standard for the Diagnosis of Moyamoya Disease?
Other diseases
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 6 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 2.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
13 hospitals in Beijing for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis
No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led6
- Clinical and imaging features and treatment response of anti-NMDAR encephalitis combined with MOGAD.
- Typical metabolic pattern of 18F-FDG PET in Anti-NMDAR encephalitis in the acute and subacute phases and its correlation with T2 FLAIR-MRI features.
- Elevated blood and cerebrospinal fluid biomarkers of microglial activation and blood‒brain barrier disruption in anti-NMDA receptor encephalitis.
- Positron emission tomography in autoimmune encephalitis: Clinical implications and future directions.
- The prognosis of late-onset anti-N-methyl-D-aspartate receptor encephalitis in China.
- Aberrant multimodal brain networks in patients with anti-NMDA receptor encephalitis.
Earlier papers (2016–2020)4
- Anti-NMDA receptor encephalitis concomitant with myelin oligodendrocyte glycoprotein antibody diseases: A retrospective observational study.
- Reply.
- Brain MRI Characteristics of Patients with Anti-N-Methyl-D-Aspartate Receptor Encephalitis and Their Associations with 2-Year Clinical Outcome.
- Paraneoplastic Anti-N-Methyl-D-Aspartic Acid Receptor Encephalitis.
Other diseases
Takayasu arteritis
大动脉炎Led 1 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
30 hospitals in Beijing for Takayasu arteritis108 hospitals in China for Takayasu arteritis
No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 2 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
27 hospitals in Beijing for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 4 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.5%.
- Open trials led
- 0
- recruiting or about to
19 hospitals in Beijing for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation
- Phase
- Phase 1
- Started
- 2024-12
- Registry
- NCT06556394
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Hangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led4
- The difference between cystatin C- and creatinine-based estimated glomerular filtration rate and survival in amyotrophic lateral sclerosis: a population-based cohort study.
- Genetic evidence for the liver-brain axis: lipid metabolism and neurodegenerative disease risk.
- Amyotrophic lateral sclerosis and myasthenia gravis overlaps syndrome: a series of case report.
- Analysis of lncRNAs profiles associated with ferroptosis can predict prognosis and immune landscape and drug sensitivity in patients with clear cell renal cell carcinoma.
Earlier papers (2016–2020)2
All its trials on ClinicalTrials.gov, any status6
- Tofacitinib in Patients With Amyotrophic Lateral Sclerosis
- Safety and Tolerance of RAG-17 in Amyotrophic Lateral Sclerosis Patients With SOD1 Gene Mutation
- Safety and Preliminary Efficacy of Aleeto in Amyotrophic Lateral Sclerosis
- Amyotrophic Lateral Sclerosis Registry
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation
- A Phase II Study of ALT001 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Other diseases
Spinal muscular atrophy
脊髓性肌萎缩症Led no English-language PubMed papers on spinal muscular atrophy in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
8 hospitals in Beijing for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingEvaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients
- Phase
- Phase 1/Phase 2
- Started
- 2024-05
- Registry
- NCT06421831
Age 2 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Duchenne muscular dystrophy
杜氏肌营养不良Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Beijing for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy
No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Niemann–Pick disease type C
尼曼-匹克病 C 型Led no English-language PubMed papers on Niemann–Pick disease type C in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Beijing for Niemann–Pick disease type C15 hospitals in China for Niemann–Pick disease type C
No open trial on Niemann–Pick disease type C lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Leber hereditary optic neuropathy
Leber 遗传性视神经病变Led 1 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 1.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Beijing for Leber hereditary optic neuropathy32 hospitals in China for Leber hereditary optic neuropathy
No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other linked evidence
Getting in touch
Name card to show staff or a driver
首都医科大学附属北京天坛医院
Beijing Tiantan Hospital
北京
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR Wikidata
Beijing Neurosurgical Institute and Beijing Tiantan Hospital; Jing-Jin Center for Neuroinfalmmation Beijing Tiantan Hospital; Tiantan Hospital Affiliated to Capital Medical University; Beijing Tiantan Hospital Affiliated to Capital Medical University; A.L.) and Beijing Tiantan Hospital (F.P; Beijing Tiantan Hospital Capital Medical University; Beijing Tiantan Hospital Affiliated with Capital Medical University; Beijing Tiantan Hospital of Capital Medical University